Valuation: Clene Inc.

Market Cap 5.13Cr 4.58Cr 4.2Cr 3.82Cr 7.17Cr 485.78Cr 7.31Cr 50Cr 20Cr 256.4Cr 19Cr 19Cr 809.85Cr P/E 2026 *
-1.4x
P/E 2027 * -2.12x
Enterprise Value 4.67Cr 4.17Cr 3.83Cr 3.48Cr 6.53Cr 442.23Cr 6.66Cr 46Cr 18Cr 233.41Cr 18Cr 17Cr 737.25Cr EV / Sales 2026 *
187x
EV / Sales 2027 * 2.28x
Free-Float
83.46%
Yield 2026 *
-
Yield 2027 * -
1 day-5.74%
1 week-5.99%
Current month-5.74%
1 month-11.52%
3 months-28.02%
6 months-41.21%
Current year-38.50%
1 week 3.6
Extreme 3.605
4.05
1 month 3.02
Extreme 3.0152
4.11
Current year 3.02
Extreme 3.0152
8.67
1 year 3.02
Extreme 3.0152
11.98
3 years 2.28
Extreme 2.2801
13.5
5 years 2.28
Extreme 2.2801
122.4
10 years 2.28
Extreme 2.2801
356.4
Manager TitleAgeSince
Chief Executive Officer 59 01/04/2013
Chief Tech/Sci/R&D Officer 67 01/01/2013
Director of Finance/CFO 57 01/02/2022
Director TitleAgeSince
Chairman 65 01/11/2015
Director/Board Member 53 01/09/2019
Director/Board Member 49 01/12/2020
Date Insider Type Main position Quantity % Market Cap. Importance
16/09/26 Free

Chief Executive Officer

15,244 0.1186%
16/09/26 Free

Chairman

4,34,451 3.3813%
16/09/26 Other

Director

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
-5.74%-5.99%-71.12%-53.46% 5.13Cr
-2.37%-5.03%+39.49%+62.39% 6.22TCr
-0.10%0.00%+10.28%+68.13% 5.49TCr
-0.23%+1.45%+19.62%+95.99% 5.53TCr
-3.33%-5.54%+19.39%+35.69% 4.26TCr
-2.45%-2.59%+16.36%+98.45% 4.11TCr
-1.64%+2.32%+219.80%+789.69% 4.03TCr
+0.19%+23.72%+98.87%+83.56% 3.31TCr
+0.21%+1.05%+14.81%+46.96% 3.26TCr
-2.90%+17.12%-42.35%+337.07% 2.4TCr
Average -1.37%+3.25%+32.52%+156.45% 3.86TCr
Weighted average by Cap. -1.11%+2.74%+44.56%+162.42%

Financials

2026 *2027 *
Net sales 2L 2L 2L 2L 3L 2.36Cr 4L 24.41L 10L 1.25Cr 9L 9L 3.94Cr 2.33Cr 2.08Cr 1.91Cr 1.73Cr 3.25Cr 220.26Cr 3.32Cr 23Cr 9.18Cr 116.26Cr 8.73Cr 8.55Cr 367.2Cr
Net income -3.45Cr -3.08Cr -2.83Cr -2.57Cr -4.82Cr -326.5Cr -4.91Cr -34Cr -14Cr -172.33Cr -13Cr -13Cr -544.32Cr -3.1Cr -2.77Cr -2.54Cr -2.31Cr -4.33Cr -293.47Cr -4.42Cr -30Cr -12Cr -154.9Cr -12Cr -11Cr -489.24Cr
Net Debt -46L -41.07L -37.69L -34.28L -64.27L -44Cr -65.55L -4.5Cr -1.81Cr -23Cr -1.73Cr -1.69Cr -73Cr 18L 16.07L 14.75L 13.41L 25.15L 17Cr 25.65L 1.76Cr 71L 8.99Cr 67.56L 66.12L 28Cr
Projected Income Statement - Annual - Clene Inc.
Logo Clene Inc.
Clene Inc. is a clinical-stage pharmaceutical company, which is engaged in discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The CSN therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities that do not present in those same elements in bulk form. CNM-Au8, the lead drug asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals for the treatment of ALS, MS, and PD. CNM-Au8's mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is an antiviral and antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions in an aqueous solution to treat infectious disease and to provide immune support for symptom resolution.
Employees
-
Date Price Change Volume
02/26/02 $3.610 -5.74% 54,014
30/26/30 $3.830 -1.79% 47,273
29/26/29 $3.900 -3.23% 34,254
28/26/28 $4.030 +1.51% 44,069
27/26/27 $3.970 +3.39% 31,305
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Clene Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.610USD
Average target price
32.20USD
Spread / Average Target
+791.97%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Clene Inc.
  1. Stock Market
  2. Stocks
  3. CLNN Stock